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Use of calcium channel blockers in cardiovascular disease 
 
 
Introduction 
 
Calcium channel blockers (CCBs) are widely used pharmacological agents in the 
management of cardiovascular disease. They exert their action via selectively blocking 
cellular entry of calcium through calcium channels on cell membranes and as such, 
have various therapeutic applications, including the treatment of angina, hypertension 
and supraventricular arrhythmias (such as atrial fibrillation).  
In order to help optimise the use of CCBs in patients for whom they are indicated, it is 
important that practitioners have a sound understanding of their pharmacological 
action and role in therapy. This article will briefly describe the action of therapeutically 
important calcium channels and the mechanism of action of CCBs in cardiovascular 
disease. A summary of the evidence for the current place in therapy will be provided, 
along with important practical considerations for their use. 
 
Calcium Channels 
 
Intracellular calcium is required for myocardial and smooth muscle cell contraction, 
and is also involved in the automaticity of cardiac pacemaker cells (Rang, Dale, Ritter, 
Flower, & Henderson, 2012). In smooth muscle cells, calcium enters the cytosol 
through transmembrane calcium channels, whereas in striated muscle cells, calcium 
is released from intracellular stores by the sarcoplasmic reticulum through ryanodine 
receptors. In myocardial cells, calcium enters the cell via both mechanisms (figure 1).  
The transmembrane calcium channels in myocardial, pacemaker and smooth muscle 
cells are the target of pharmacological intervention in order to regulate intracellular 
calcium concentrations.  
There are a number of known transmembrane calcium channels, of which the voltage-
gated L-type calcium channels are therapeutically important. Depolarisation during the 
action potential activates and opens the voltage-gated L-type calcium channel, 
resulting in calcium influx. This leads to myosin phosphorylation and muscle 
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contraction, and the stimulation of ryanodine receptors that further release calcium 
from the sarcoplasmic reticulum (i.e. calcium-induced calcium release). 
 
Figure 1: L-type calcium channel blocker function and sites of action of calcium channel 
blockers. 
 
Calcium channel blockers block the cellular entry of calcium through L-type calcium 
channels and in doing so, reduce the concentration of free intracellular calcium (T 
Godfraind, Miller, & Wibo, 1986). Less available intracellular calcium will reduce the 
force of contraction in myocardial and vascular smooth muscle cells, and reduce the 
capacity for spontaneous discharge of pacemaker cells in the sinoatrial (SA) and 
atrioventricular (AV) nodes. Clinically this will cause vasodilation in resistance and 
coronary vessels (resulting in a reduction of afterload and increased coronary 
perfusion, respectively), antidysrhythmic activity, and reduced contractility. 
 
Calcium channel blocker properties 
 
There are three main classes of CCBs in use, determined by their chemical structure: 
dihydropyridines (DHPs), phenylalkylamines and benzothiazepines (otherwise known 
as non-dihydropyridines (NDHPs)). Despite their different structures, all CCBs bind 
close to the channel pore and to the proposed activation gate of the channel’s α1-
subunit (Tikhonov & Zhorov, 2009). Upon binding, CCBs interfere with the calcium 
channel’s normal cycle through resting, active and inactive states. This modulation of 
the gating properties of the channel results in a reduction of calcium concentrations 
inside the cell. 
Calcium channel blockers exhibit distinct patterns of regional potency, with certain 
drugs preferentially acting on vascular smooth muscle, and others having a greater 
affinity to myocardial and pacemaker cells in the heart (table 1). Dihydropyridines have 
preferential affinity for channels that are in an inactive state, such as those in vascular 
smooth muscle (moreso than in cardiac muscle). Non-dihydropyridines favour open 
and inactive channel states, accessing their binding from inside the cell during channel 
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opening (Beyl et al., 2006). They stabilise inactive channels, slowing their recovery 
from inactivation, resulting in frequency dependant inhibition, which increases with 
heart rate (Hering et al., 1997). As such, DHPs have a potent vasodilating effect 
without affecting cardiac ionotropy at therapeutic doses, whereas NDHPs are more 
selective for cardiac muscle and can reduce heart rate and contractility (Waller & 
Sampson, 2017). The main uses for CCBs in clinical practice include the treatment of 
hypertension, angina and atrial fibrillation; their mechanism of action in these 
conditions, along with their place in therapy, is outlined below. 
 
Mechanism of action 
  
Hypertension 
 
By decreasing the amount of available intracellular calcium in vascular smooth 
muscle, CCBs effectively cause smooth muscle relaxation. By dilating arterial 
resistance vessels (in preference to venous capacitance vessels), CCBs 
decrease systemic vascular resistance, and arterial blood pressure is reduced. 
All CCBs work in this way, although the DHPs (e.g. amlodipine, nifedipine) are 
the most potent vasodilators, and have the greatest affinity to vascular smooth 
muscle, thus they are the preferential agents in the treatment of hypertension 
(Lydtin & Trenkwalder, 1990).  
Calcium channel blockers are one of the agents used for the initial treatment of 
hypertension, as recommended by NICE (see table 2). Initial dosing should be 
low, titrated upwards if necessary in monthly intervals according to response 
(NICE 2018c).  Calcium channel blockers have been shown to be effective in 
reducing blood pressure, often after the first dose or a few days’ treatment 
(Lydtin & Trenkwalder, 1990; Trenkwalder, 2004).  
A recent Cochrane review concluded that when used first-line for hypertension, 
CCBs prevented stroke and total cardiovascular syndromes, but not coronary 
heart disease or mortality (Wright, Musini, & Gill, 2018). The evidence was low-
quality however, and it is important to consider that CCBs may also increase 
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the risk of heart failure compared to diuretics, ACE inhibitors and ARBs (Chen 
et al., 2010). 
 
Angina 
 
The effects of CCBs on blood pressure as outlined above also account for its 
usefulness in preventing angina pectoris. Lower blood pressure (resulting from 
a decreased peripheral resistance) results in a decrease in cardiac work of the 
left ventricle, ventricular afterload, and subsequent myocardial oxygen demand 
(Theophile Godfraind, 2014). Myocardial oxygen demand is also reduced by 
the decrease in heart rate and contractility seen with the NDHPs (verapamil and 
diltiazem). Oxygen supply to the myocardium is improved with the action of 
CCBs dilating coronary arteries, preventing coronary vasospasm, and 
improving myocardial blood flow. 
Calcium channel blockers, along with beta-blockers, are considered first-line 
agents for the prevention of angina symptoms (Table 2). Evidence from meta-
analyses suggests that CCBs are generally as well-tolerated and effective as 
beta blockers in reducing angina symptoms (Heidenreich et al., 1999; O’Toole, 
2008), but there is a lack of evidence comparing the efficacy of individual CCBs 
for this purpose. Choice of CCB therefore depends on co-morbidities and 
concomitant drugs.  
For example, NDHPs are contraindicated in heart failure, heart block and 
bradycardia on account of their negative ionotropic and chronotropic properties, 
which may cause clinical deterioration. For these patients, DHPs would be a 
safer option (Packer et al., 1996). The addition of DHPs to beta blockers as 
combination therapy for angina has been shown to be safe and effective in 
increasing exercise tolerance and duration when monotherapy is insufficient to 
control symptoms (Klein, Jackson, & Tavazzi, 2002). This is not the case for 
NDHPs, which should be avoided with beta blockers (see Interactions, below). 
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Atrial Fibrillation 
 
The AV and SA nodes generate slowly propagating action potentials that are 
dependent upon the movement of calcium across cell membranes. Calcium 
channel blockers that have a greater affinity for myocardial pacemaker cells 
(e.g. NDHPs) reduce the firing rate and conduction velocity at the AV and SA 
nodes, thereby prolonging repolarisation. This helps to block reenterant 
mechanisms that can cause supraventricular tachycardias (SVT) (Theophile 
Godfraind, 2014). The NDHPs are included in the Vaughn Williams 
classification of antiarrythmics (class IV) and are used in the management of a 
variety of arrhythmias, particularly SVTs such as atrial fibrillation (AF), atrial 
flutter, and paroxysmal SVT. 
 
In AF, rate control with NDHPs has shown to be effective  (Ulimoen et al., 2013) 
and associated with reduced all-cause mortality compared to no rate-control 
therapy (Chao et al., 2015).  They are also associated with improvements in 
quality of life and exercise tolerance (Fuster et al., 2006). Conclusive data 
regarding comparative efficacy compared to beta blockers is currently limited, 
therefore both are currently recommended as first-line agents for rate control, 
with selection dependant on patient-specific factors such as co-morbidities and 
contraindications (Table 2).  
 
Precautions for use 
 
Adverse effects 
 
The adverse effects of the DHPs are associated with their vasodilatory 
properties, and are dose-dependent (Law, Wald, Morris, & Jordan, 2003). For 
example, dizziness, headache and flushing may commonly occur with first use, 
but often improve after a few days. Peripheral oedema, particularly in the 
ankles, can also occur due to the dilatation of pre-capillary arterioles (rather 
than a result of sodium retention), and thus may be refractory to diuretic 
treatment (Messerli & Grossman, 2002). Treatment of CCB-induced ankle 
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oedema may include options such as leg elevation whilst in a supine position, 
reduction in the dose of CCB, or the addition of an ACE inhibitor (Sica, 2003). 
Short-acting DHPs (e.g. nifedipine) can cause excessive hypotension and 
reflex tachycardia from sympathetic stimulation, and their sudden withdrawal 
may exacerbate angina. Longer acting DHPs (e.g. amlodipine) are more slowly 
absorbed from the gastrointestinal tract and are associated with reduced 
baroreceptor reflex responses (Opie, Yusuf, & Kübler, 2000), and therefore 
have a more desirable safety profile for hypertension and angina. 
The NDHPs can cause excessive bradycardia, heart block and a reduction in 
contractility, particularly when given intravenously or at high doses. Verapamil 
commonly causes constipation, and diltiazem has been associated with 
dermatological reactions (e.g. photosensitivity, rash). The vasodilatory adverse 
effects described above are less common with the NDHPs and often improve 
with continued use. 
It is important to consider the side-effect profile of individual CCBs when 
prescribing and administering these drugs, as they may determine their 
suitability to certain patients. For example, considering the above, patients with 
unstable angina, bradycardia or heart failure may not be suited to therapy with 
CCBs, and alternative agents may need to be sought. 
  
Interactions 
 
Calcium channel blockers are metabolised in the liver by cytochrome p450 
enzymes, therefore concomitant use of enzyme inducers or inhibitors should 
be cautioned (Table 3). Patients who have decreased hepatic function should 
also be monitored for signs of increased plasma CCB concentrations (e.g. heart 
rate, blood pressure). 
One of the notable interactions with CCBs occurs with the HMG-CoA reductase 
inhibitors atorvastatin and simvastatin. Current recommendations state that if a 
patient is established on CCB therapy, the lowest possible dose of statin should 
be used initially, and the dose titrated upwards (NICE 2018a). If a patient 
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already taking atorvastatin/simvastatin is prescribed a CCB, the statin dose 
should be lowered and retitrated against serum cholesterol levels. For example, 
a maximum dose of 20mg simvastatin is currently recommended with the 
concomitant administration of either amlodipine, verapamil or diltiazem (Joint 
Formulary Committee, 2018). 
Non-dihydropyridine calcium channel blockers (particularly verapamil) depress 
cardiac function and therefore the concomitant prescription of other 
cardiodepressants, such as beta blockers, can increase the risk of bradycardia, 
asystole, severe hypotension or heart failure. As such, verapamil is 
contraindicated with beta blockers, and the use of diltiazem with beta blockers 
should be approached with caution (e.g. on specialist advice, with careful 
monitoring of heart rate and blood pressure). 
 
Conclusion 
 
Calcium channel blockers are widely used, and generally well-tolerated, in the therapy 
of cardiovascular disease, and are beneficial in the treatment of hypertension, angina 
and supraventricular tachycardias such as atrial fibrillation. There are important 
differences between the classes of calcium channel blockers, and their diversity with 
respect to their selectivity and mechanism of action directs their selection and use in 
therapy. Caution therefore needs to be exercised when prescribing and administering 
these drugs in patients prescribed other medications, or who have co-morbidities, in 
order to confer the maximum benefit of therapy to patients. 
 
Key messages 
 
 Calcium channel blockers act on L-type transmembrane calcium channels to 
reduce the concentration of intracellular calcium available to promote 
contraction. 
 Clinical uses of calcium channel blockers include the treatment of 
supraventricular tachycardia, hypertension and the prevention of angina. 
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 Dihydropyridine calcium channel blockers are mainly used for the treatment of 
hypertension and prevention of angina, whereas non-dihydropyridine calcium 
channel blockers are mainly used for dysrhythmias. 
 
CPD Questions 
 
 What are the key differences between the dihydropyridine calcium channel 
blockers (DHPs) and the non-dihydropyridine calcium channel blockers 
(NDHPs)? 
 Under what circumstances would treatment with NDHP usually be avoided? 
 What are the main side effects of DHPs and how are they managed? 
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